Correction to: Ruxolitinib inhibits IFNγ-stimulated Sjögren’s salivary gland MSC HLA-DR expression and chemokine-dependent T cell migration

This is a correction to: Sara S. McCoy, Maxwell Parker, Ilya Gurevic, Rahul Das, Andrea Pennati, Jacques Galipeau, Ruxolitinib inhibits IFNγ-stimulated Sjögren’s salivary gland MSC HLA-DR expression and chemokine-dependent T cell migration, Rheumatology, 2022, https://doi.org/10.1093/rheumatology/keac111

In the originally published version of this manuscript, the Funding statement was incorrect and given as follows:

Funding: This work was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant 1KL2TR002374 (S.S.M.) and NIH/NIDDK R01DK109508 (J.G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The Funding statement has been updated to read:

Funding: This work was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant 1KL2TR002374 and NIH/NIDCR R03DE031340 (SM) and NIH/NIDDK R01DK109508 (JG). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.